Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Depreciation & Amortization - Total (2020 - 2025)

Vivos Therapeutics' Depreciation & Amortization - Total history spans 6 years, with the latest figure at -$200000.0 for Q4 2025.

  • Quarterly results put Depreciation & Amortization - Total at -$200000.0 for Q4 2025, down 300.0% from a year ago — trailing twelve months through Dec 2025 was $700000.0 (up 75.0% YoY), and the annual figure for FY2025 was $700000.0, up 40.0%.
  • Depreciation & Amortization - Total for Q4 2025 was -$200000.0 at Vivos Therapeutics, down from $400000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization - Total ranged from a high of $400000.0 in Q3 2025 to a low of -$200000.0 in Q4 2025.
  • The 5-year median for Depreciation & Amortization - Total is $100000.0 (2021), against an average of $149029.8.
  • The sharpest move saw Depreciation & Amortization - Total soared 800.67% in 2021, then crashed 300.0% in 2025.
  • Year by year, Depreciation & Amortization - Total stood at $100000.0 in 2021, then soared by 200.0% to $300000.0 in 2022, then plummeted by 33.33% to $200000.0 in 2023, then tumbled by 50.0% to $100000.0 in 2024, then crashed by 300.0% to -$200000.0 in 2025.
  • According to Business Quant data, Depreciation & Amortization - Total over the past three periods came in at -$200000.0, $400000.0, and $300000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.